Abstract
Pseudomonas aeruginosa-associated infective endocarditis represents difficult-to-treat, deep-seated infections. Phage-antibiotic combinations have shown to eradicate multi-drug resistant (MDR) P. aeruginosa, limit the development of phage resistance, and restore antibiotic sensitivity. The objective of this study was to evaluate the activity of phage-ciprofloxacin (CIP) combinations in 4-day ex vivo simulated endocardial vegetation (SEV) models against drug-resistant P. aeruginosa isolates. Two P. aeruginosa isolates, extensively drug-resistant AR351 and MDR I0003-1, were selected for their drug resistance and sensitivity to phage. Three phages [LL-5504721-AH (LL), E2005-C (EC), and 109] and CIP were evaluated alone and in combination for their activity and influence on drug and phage resistance using 24-h time-kill analysis. The three-phage cocktail (q24h) in combination with CIP (400 mg q12h) was then tested in dynamic 4-day ex vivo SEV models, with reduction of log10 CFU∕mL compared using ANOVA with Bonferroni analysis. Compared to other combinations, CIP-LL-EC-109 demonstrated synergistic and bactericidal activity from starting CFU∕g against AR351 and I0003-1 (−Δ5.65 and 6.60 log10 CFU∕g, respectively; P < 0.001). Additionally, CIP-LL-EC-109 mitigated phage resistance, while all other therapies had a high degree of resistance to >1 phages, and all phage-containing regimens prevented CIP mean inhibitory concentration increases compared to CIP alone for both AR351 and I0003-1 at 96 h.
| Original language | English |
|---|---|
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 67 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2023 |
Bibliographical note
Publisher Copyright:This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply.
Funding
A.E., K.S., A.J.K., D.J.H., R.K., J.A., and S.M.L. have nothing to disclose. M.J.R.: received research support, consulted or participated in a speaker bureau for AbbVie, Basilea, Entasis, La Jolla, Merck, Paratek, Shionogi, T2 Biosystems, and is partially funded by NIAID R21AI163726.
| Funders | Funder number |
|---|---|
| National Institute of Allergy and Infectious Diseases | R21AI163726 |
| National Institute of Allergy and Infectious Diseases |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Pseudomonas aeruginosa
- bacteriophages
- ex vivo simulated endocardial vegetation models
- infective endocarditis
- multi-drug resistance
- phage resistance
- phage therapy
- phage-antibiotic combinations
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver